Ultrasound predicts ulcerative colitis treatment response
Ultrasound scans may help physicians predict which patients with severe ulcerative...Read more on AuntMinnie.comRelated Reading: Ultrasound predicts which kids benefit from colitis meds Cinematic rendering complements CT in diagnosing colitis Immuno-PET could aid patients with inflammatory diseases 3 ways cinematic rendering can bolster colon evaluation PET/CT enhances detection of inflammatory bowel disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 11, 2021 Category: Radiology Source Type: news

Researchers engineer novel disease model to identify potential targets for ulcerative colitis drugs
(Cleveland Clinic) As reported in Nature Communications, researchers from Cleveland Clinic's Lerner Research Institute have developed a novel, patient-derived model of ulcerative colitis, which will help advance studies into new treatments for the chronic inflammatory bowel disease. The team used the model to identify a promising target that could be inhibited to slow disease progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

UC: Can the Autoimmune Protocol Diet Help?
Can a diet called the autoimmune protocol, or AIP, improve your ulcerative colitis? Possibly. Some people say elimination diets, like AIP and others, put their disease in remission. (Source: WebMD Health)
Source: WebMD Health - December 21, 2020 Category: Consumer Health News Source Type: news

Can Marijuana or CBD Help With Ulcerative Colitis?
Can marijuana or CBD help manage the symptoms of ulcerative colitis? (Source: WebMD Health)
Source: WebMD Health - December 18, 2020 Category: Consumer Health News Source Type: news

UC: How Can It Affect Your Sex Life?
If you have ulcerative colitis, you might be wondering whether it’s possible to have a satisfying sex life. The short answer is yes. (Source: WebMD Health)
Source: WebMD Health - December 16, 2020 Category: Consumer Health News Source Type: news

Does Histologic Remission Offer Benefit for UC Patients? Does Histologic Remission Offer Benefit for UC Patients?
Do ulcerative colitis patients in endoscopic remission obtain additional benefit from achieving histologic remission?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy
This long-term extension study assessed the efficacy and safety of one additional year of ustekinumab maintenance treatment in patients originally manifesting moderate-to-severe ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Consumer Health: Treating Crohn's disease and ulcerative colitis
Inflammatory bowel disease, or IBD, is an umbrella term used to describe disorders that involve chronic inflammation of your digestive tract. IBD can be debilitating and sometimes leads to life-threatening complications. Crohn's disease and ulcerative colitis are two types of IBD. Crohn's disease is characterized by inflammation of the lining of your digestive tract, which often [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 9, 2020 Category: Databases & Libraries Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Vitamin D regulates calcium in intestine differently than previously thought
(Rutgers University) A Rutgers study has discovered that vitamin D regulates calcium in a section of the intestine that previously was thought not to have played a key role. The findings have important implications on how bowel disease, including ulcerative colitis and Crohn's disease, may disrupt calcium regulation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

Key Studies in Ulcerative Colitis From ACG 2020 Virtual Key Studies in Ulcerative Colitis From ACG 2020 Virtual
Highlights in ulcerative colitis from the ACG 2020 virtual meeting include the OCTAVE tofacitinib trial program, the long-term and comparative efficacy of vedolizumab, and long-term colectomy trends.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Kurogane holly contains anti-cancer compounds for IBS patients
(Natural News) Colitis-associated cancer (CAC) is one of the most serious complications of inflammatory bowel disease (IBD), an umbrella term for disorders that cause chronic inflammation of the digestive tract. An important risk factor for colon cancer, IBDs – either ulcerative colitis or Crohn s disease – often precede CAC, which is a type of inflammation-driven... (Source: NaturalNews.com)
Source: NaturalNews.com - November 17, 2020 Category: Consumer Health News Source Type: news

Tool Predicted Vedolizumab Nonresponse in Routine Practice Tool Predicted Vedolizumab Nonresponse in Routine Practice
Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 13, 2020 Category: Internal Medicine Tags: Gastroenterology News Source Type: news

Optimum Number of Biopsies to Assess Inflammation in UC Optimum Number of Biopsies to Assess Inflammation in UC
What are the minimum number of biopsies required to adequately assess histological disease activity in ulcerative colitis patients?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Athos Therapeutics Announces Appointment of Chief Business Officer
LOS ANGELES, Nov. 2, 2020 -- (Healthcare Sales & Marketing Network) -- Athos Therapeutics Inc., a late pre-clinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and c... Biopharmaceuticals, Personnel Athos Therapeutics, Ulcerative Colitis, Crohn's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2020 Category: Pharmaceuticals Source Type: news

Tofacitinib Retreatment Effective for Ulcerative Colitis Tofacitinib Retreatment Effective for Ulcerative Colitis
Clinical response can be recaptured in patients who have had to interrupt treatment with tofacitinib, a JAK inhibitor, for up to 2 months, an analysis of data from the OCTAVE extension trial shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Long-term Safety of Vedolizumab for Inflammatory Bowel Disease Long-term Safety of Vedolizumab for Inflammatory Bowel Disease
This paper details the final results from the GEMINI study, which evaluated the long-term safety of vedolizumab in patients with ulcerative colitis or Crohn's disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Can Ulcerative Colitis Be Cured With Surgery?
Title: Can Ulcerative Colitis Be Cured With Surgery?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - October 21, 2020 Category: Nutrition Source Type: news

DDT COA #000040: Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS)
Clinical Outcome Assessments (COA) Qualification Submissions Office of Drug Evaluation (ODE) III Division of Gastroenterology and Inborn Error Products (DGIEP) DDT COA Number DDT COA #000040 (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 6, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Ulcerative Colitis: Adopting the AGA's Guidelines Ulcerative Colitis: Adopting the AGA's Guidelines
Three expert gastroenterologists discuss how this latest update reshapes the management of moderate to severe ulcerative colitis.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2020 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Predictors of Histological Remission in Ulcerative Colitis Predictors of Histological Remission in Ulcerative Colitis
This study aimed to identify the feasibility and predictors of achieving histologic remission in patients with ulcerative colitis treated-to-target of endoscopic healing.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Drug found to correct gene defect that causes immune-driven gut leakiness
(University of California - Riverside) A team of researchers led by biomedical scientist Declan McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine. " Our work could help improve identification of patients who will be better responders to this drug, " says McCole, a professor of biomedical sciences in the School of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2020 Category: International Medicine & Public Health Source Type: news

Hyperbaric Oxygen Therapy for Flares in Ulcerative Colitis Hyperbaric Oxygen Therapy for Flares in Ulcerative Colitis
How effective is hyperbaric oxygen for improving outcomes in hospitalized ulcerative colitis patients with acute moderate-severe flares refractory to standard medical therapy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

University of South Carolina study reveals how cannabinoids may be useful to prevent colon cancer
(University of South Carolina) Inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis are caused by inflammation of the gastrointestinal tract. Patients with IBD are at a higher risk of developing colorectal cancer. A UofSC study shows that THC suppressed inflammation in the colon, preventing the onset of cancers caused by a carcinogen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Survival Mortality Ulcerative Colitis
Survival and Cause-Specific Mortality in Ulcerative Colitis (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 11, 2020 Category: General Medicine Source Type: news

Ulcerative Colitis
Title: Ulcerative ColitisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/2/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 2, 2020 Category: Nutrition Source Type: news

What Is Ulcerative Colitis, the Ailment Afflicting Shinzo Abe of Japan?
The disease that has afflicted Prime Minister Shinzo Abe of Japan is a chronic malady that can strike at a young age and flare up unpredictably. (Source: NYT Health)
Source: NYT Health - August 28, 2020 Category: Consumer Health News Authors: Rick Gladstone Tags: Digestive Tract Colitis Bowels Crohn ' s Disease Colon Clinical Gastroenterology and Hepatology (Journal) Massachusetts General Hospital Abe, Shinzo Source Type: news

Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
In an oversubscribed round, top-tier investors provide significant financial resources to accelerate clinical development of potentially best-in-class therapies for inflammatory/autoimmune diseases SAN DIEGO and TAICANG, SUZHOU, China, Aug. 24, 2020 -- ... Biopharmaceuticals, Venture Capital, Personnel Connect Biopharma, atopic dermatitis, ulcerative colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
Basel, 10 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced topline results from its phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumour ...
Source: Roche Investor Update - August 10, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
Basel, 10 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced topline results from its phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumour ...
Source: Roche Media News - August 10, 2020 Category: Pharmaceuticals Source Type: news

How Serious Is Ulcerative Colitis?
Title: How Serious Is Ulcerative Colitis?Category: Diseases and ConditionsCreated: 8/6/2020 12:00:00 AMLast Editorial Review: 8/6/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 6, 2020 Category: Nutrition Source Type: news

What Is the Life Expectancy of Someone With Ulcerative Colitis?
Title: What Is the Life Expectancy of Someone With Ulcerative Colitis?Category: Diseases and ConditionsCreated: 8/6/2020 12:00:00 AMLast Editorial Review: 8/6/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 6, 2020 Category: Nutrition Source Type: news

An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease
Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with pa...
Source: Signal Transduction Knowledge Environment - August 3, 2020 Category: Science Authors: Brubaker, D. K., Kumar, M. P., Chiswick, E. L., Gregg, C., Starchenko, A., Vega, P. N., Southard-Smith, A. N., Simmons, A. J., Scoville, E. A., Coburn, L. A., Wilson, K. T., Lau, K. S., Lauffenburger, D. A. Tags: STKE Research Articles Source Type: news

High-Fiber, Low-Fat Diet for Ulcerative Colitis
Title: High-Fiber, Low-Fat Diet for Ulcerative ColitisCategory: Health NewsCreated: 7/10/2020 12:00:00 AMLast Editorial Review: 7/13/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - July 13, 2020 Category: Nutrition Source Type: news

High-Fiber, Low-Fat Diet May Help People With Ulcerative Colitis
FRIDAY, July 10, 2020 -- A low-fat, high-fiber diet may improve the quality of life of patients with ulcerative colitis, a new study finds. " Patients with inflammatory bowel disease always ask us what they should eat to make their symptoms better, " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 10, 2020 Category: General Medicine Source Type: news

Inflammatory Bowel Disease Tied to Increased Dementia Risk
Those with Crohn ’s disease or ulcerative colitis had higher rates of Alzheimer’s disease and other forms of dementia. (Source: NYT Health)
Source: NYT Health - July 2, 2020 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Alzheimer ' s Disease Dementia Digestive Tract Crohn Source Type: news

Better Data Shed More Light on Ulcerative Colitis Surgery Better Data Shed More Light on Ulcerative Colitis Surgery
An inflammatory bowel disease (IBD) surgery registry that adds IBD-specific variables to general quality measurements for restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) performed for ulcerative colitis (UC) allows a better interpretation of predictive factors for delayed pouch formation, according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 1, 2020 Category: Surgery Tags: Gastroenterology News Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-term Response to I.V. Steroids in Acute Severe UC Long-term Response to I.V. Steroids in Acute Severe UC
This study assessed relapse-free survival in patients with acute severe ulcerative colitis who have responding favorably to treatment with intravenous steroids.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Could Crohn's, Colitis Raise Dementia Risk?
TUESDAY, June 23, 2020 -- People with inflammatory bowel disease might be vulnerable to developing dementia, a new study suggests. Inflammatory bowel disease, or IBD, is an umbrella term for ulcerative colitis and Crohn's disease. Both cause chronic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 23, 2020 Category: General Medicine Source Type: news

Is Ulcerative Colitis Curable?
Title: Is Ulcerative Colitis Curable?Category: Diseases and ConditionsCreated: 6/19/2020 12:00:00 AMLast Editorial Review: 6/19/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 19, 2020 Category: Nutrition Source Type: news

Adaptation of the BSG guidelines on the management of acute severe ulcerative colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel, BSG
Management of acute severe ulcerative colitis (ASUC) during the novel coronavirus 2019 (COVID-19) pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 10, 2020 Category: Consumer Health News Source Type: news

Understanding a gene's role in inflammatory bowel disease
(University of California - Riverside) A protein-coding gene associated with autoimmune diseases such as Crohn's disease and ulcerative colitis, collectively referred to as inflammatory bowel disease, or IBD, will be the focus of new research in the School of Medicine at the University of California, Riverside. The work is made possible by a National Institutes of Health grant exceeding $2.5 million. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2020 Category: International Medicine & Public Health Source Type: news

Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Vedolizumab and Infliximab in UC After Failure of Anti-TNF Vedolizumab and Infliximab in UC After Failure of Anti-TNF
In this study, in patients with ulcerative colitis refractory to an anti-TNF agent, vedolizumab was more effective than infliximab in achieving clinical remission.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fecal Calprotectin and Histologic Remission in UC Fecal Calprotectin and Histologic Remission in UC
Might fecal calprotectin be useful as a non-invasive marker of histologic remission in patients with ulcerative colitis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news